Question 1

What is coenzyme Q10 deficiency, primary, 3?

Accepted Answer

Coenzyme Q10 deficiency, primary, 3 is a condition caused by mutations in the PDSS2 gene that disrupt the normal production of coenzyme Q10, a molecule essential for cellular energy production. This condition affects multiple organ systems, with prominent involvement of the kidneys and central nervous system. Affected individuals typically present in infancy with features such as nephrotic syndrome, seizures, and feeding difficulties. Precise prevalence estimates are not well established, and the condition is inherited in an autosomal recessive manner.

Question 2

What are the symptoms of coenzyme Q10 deficiency, primary, 3?

Accepted Answer

The clinical presentation of coenzyme Q10 deficiency, primary, 3 is multi-system and includes consistently reported kidney, neurological, and metabolic features. Renal manifestations include nephrotic syndrome, proteinuria, hypoalbuminemia, and edema, while neurological findings comprise focal motor status epilepticus and bilateral tonic-clonic seizures with focal onset, accompanied by cerebral visual impairment and neonatal hypotonia. In addition, affected individuals exhibit feeding difficulties, an increased circulating lactate concentration, and a documented decrease of coenzyme Q10 levels in skeletal muscle, with imaging studies showing focal T2 hyperintense basal ganglia lesions. Not all individuals experience every clinical feature to the same degree, and severity and symptoms vary widely between individuals.

Question 3

What causes coenzyme Q10 deficiency, primary, 3?

Accepted Answer

Coenzyme Q10 deficiency, primary, 3 is directly linked to mutations in the PDSS2 gene, which plays a critical role in the biosynthesis of coenzyme Q10. The condition is inherited in an autosomal recessive pattern, meaning that an affected individual has inherited a mutated copy of PDSS2 from each parent who may be asymptomatic carriers. This genetic disruption leads to impaired cellular energy production and the subsequent development of multi-system clinical features. Genetic counseling is recommended for families to better understand the inheritance and recurrence implications. Associated genes include PDSS2.

Question 4

How is coenzyme Q10 deficiency, primary, 3 inherited?

Accepted Answer

coenzyme Q10 deficiency, primary, 3 follows an autosomal recessive inheritance pattern. This means a child must inherit a copy of the altered gene from both parents to develop the condition. Parents who each carry one copy typically do not show symptoms.

Question 5

How is coenzyme Q10 deficiency, primary, 3 diagnosed?

Accepted Answer

Diagnosis is confirmed through molecular genetic testing that identifies pathogenic variants in the PDSS2 gene. Clinical evaluation focuses on the characteristic findings such as nephrotic syndrome, seizures, feeding difficulties, and laboratory evidence of increased lactate and low coenzyme Q10 levels in skeletal muscle, complemented by neuroimaging findings like focal T2 hyperintense basal ganglia lesions. Because these clinical features can overlap with those of other conditions, genetic testing is essential to establish a definitive diagnosis.

Question 6

Are there treatments for coenzyme Q10 deficiency, primary, 3?

Accepted Answer

Currently, management focuses on supportive care and symptom management, with treatment tailored to the individual’s specific needs. Although there are no FDA-approved treatments or established foundational therapies for this condition, a multidisciplinary team approach is essential. Regular surveillance is an integral part of long-term care, helping to monitor kidney function, neurological status, and overall metabolic balance. Patients are encouraged to discuss treatment options and surveillance strategies with their healthcare team, and genetic counseling is recommended to guide families in making informed decisions.

Question 7

Are there clinical trials for coenzyme Q10 deficiency, primary, 3?

Accepted Answer

Yes, there is currently 1 active clinical trial for coenzyme Q10 deficiency, primary, 3 registered on ClinicalTrials.gov. Clinical trials test new treatments, procedures, or approaches. Your healthcare provider can help determine if a trial might be appropriate for your situation. Visit the Treatment section of this page for more details.

Question 8

What are the potential complications of coenzyme Q10 deficiency, primary, 3?

Accepted Answer

Coenzyme Q10 deficiency, primary, 3 can lead to serious complications affecting multiple organ systems. The most common complications include kidney problems like nephrotic syndrome, which can cause swelling and protein loss in urine, and neurological issues such as seizures and developmental delays. These complications can vary widely among individuals, making regular monitoring and supportive care very important.

Question 9

How does coenzyme Q10 deficiency, primary, 3 affect daily life for patients and families?

Accepted Answer

Living with coenzyme Q10 deficiency, primary, 3 can be challenging for both patients and their families. Daily life may involve managing symptoms like feeding difficulties and seizures, which require careful attention and support. Families often need to work closely with healthcare providers to create a plan that addresses the individual's needs and ensures a safe and supportive environment.

Question 10

What is the long-term prognosis for someone with coenzyme Q10 deficiency, primary, 3?

Accepted Answer

The long-term prognosis for individuals with coenzyme Q10 deficiency, primary, 3 can vary significantly. While many face challenges early in life, advancements in supportive care have improved outcomes for some patients. Ongoing medical care and tailored management strategies are essential, and families are encouraged to connect with specialists who understand the condition to help navigate the future.

Question 11

Are there specific specialists recommended for managing coenzyme Q10 deficiency, primary, 3?

Accepted Answer

Yes, it is important for individuals with coenzyme Q10 deficiency, primary, 3 to work with a multidisciplinary team of specialists. This team may include pediatricians, nephrologists for kidney issues, neurologists for seizures and developmental concerns, and genetic counselors for family planning. Collaborating with these experts can help ensure comprehensive care and support tailored to the individual's needs.

Organ System	Phenotype Count	Example Features
Brain and nerves	3	Focal motor status epilepticus, Cerebral visual impairment, Bilateral tonic-clonic seizure with focal onset

Research Type	Count	% of Total
Research summaries	5	28%

Kisho

coenzyme Q10 deficiency, primary, 3

Overview

Clinical Presentation

Genetic Landscape

Diagnosis

Prognosis

Research Landscape

Medical References

External Resources

OMIM

GARD

Questions for Your Care Team

Questions for Your Care Team

FAQ

Frequently Asked Questions

Explore clinical features

Recent Publications

coenzyme Q10 deficiency, primary, 3

Overview

Clinical Presentation

Genetic Landscape

Diagnosis

Prognosis

Research Landscape

Medical References

External Resources

OMIM

GARD

Related Diseases

Questions for Your Care Team

Questions for Your Care Team

FAQ

Frequently Asked Questions

What is coenzyme Q10 deficiency, primary, 3?

What are the symptoms of coenzyme Q10 deficiency, primary, 3?

What causes coenzyme Q10 deficiency, primary, 3?

How is coenzyme Q10 deficiency, primary, 3 inherited?

How is coenzyme Q10 deficiency, primary, 3 diagnosed?

Are there treatments for coenzyme Q10 deficiency, primary, 3?

Are there clinical trials for coenzyme Q10 deficiency, primary, 3?

What are the potential complications of coenzyme Q10 deficiency, primary, 3?

How does coenzyme Q10 deficiency, primary, 3 affect daily life for patients and families?

What is the long-term prognosis for someone with coenzyme Q10 deficiency, primary, 3?

Are there specific specialists recommended for managing coenzyme Q10 deficiency, primary, 3?

Explore clinical features

Recent Publications